What one share of Casi Pharmaceuticals holds
The Company has historically built and operated a fully integrated biopharmaceutical organization dedicated to the development and commercialization of innovative therapeutics, with a primary focus on the hematology/oncology field and the China market.
Casi Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $1.12 |
|---|---|
| Profit | −$2.59 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.12 |
| Cash and investments | $0.27 |
| Book value | −$1.81 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $1.37 | −$4.37 | $0.14 | −$2.48 | — | $7.38 |
| 2021 | $2.22 | −$2.69 | $0.66 | −$2.63 | — | $6.04 |
| 2022 | $3.16 | −$3.01 | $0.41 | −$1.96 | — | $3.31 |
| 2023 | $2.54 | −$2.02 | $0.02 | −$1.51 | — | $1.81 |
| 2024 | $1.86 | −$2.56 | $0.01 | −$1.92 | — | $0.12 |
| 2025 | $1.12 | −$2.59 | $0.00 | −$1.12 | — | −$1.81 |
Common questions about Casi Pharmaceuticals
How much does one share of Casi Pharmaceuticals earn?
Over its latest fiscal year, Casi Pharmaceuticals lost $2.59 for each share on $1.12 of sales.
Does Casi Pharmaceuticals pay a dividend?
Casi Pharmaceuticals didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is Casi Pharmaceuticals’s book value per share?
Casi Pharmaceuticals’s book value is negative (−$1.81 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of December 31, 2025.
How much cash and debt does each share of Casi Pharmaceuticals have?
Each share of Casi Pharmaceuticals has $0.27 of cash and investments, as of December 31, 2025.
What is Casi Pharmaceuticals’s free cash flow per share?
−$1.12 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.
Has Casi Pharmaceuticals bought back shares?
Casi Pharmaceuticals’s share count rose about 68% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.